v3.26.1
Schedule of Segment Financial Performance (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting [Line Items]          
Total assets $ 564,570,386   $ 564,570,386   $ 519,146,435
Loss from operations (1,202,154) $ (1,428,594) (36,423,335) $ (3,472,642)  
Unrealized loss on digital assets holdings (23,735,950) (38,749,254)  
Total loss before income taxes (24,626,256) (1,432,587) (74,542,563) (3,471,670)  
Consolidated total loss before income taxes (25,927,001) (1,855,153) (77,490,438) (4,396,857)  
Digital Asset Treasury [Member]          
Segment Reporting [Line Items]          
Total assets 563,869,389   563,869,389   513,964,900
Loss from operations (1,202,154) (36,423,335)  
Other income (expense) [1] 311,848 630,026  
Unrealized loss on digital assets holdings (23,735,950) (38,749,254)  
Total loss before income taxes (24,626,256) (74,542,563)  
Consolidated total loss before income taxes (24,626,256) (74,542,563)  
Clinical Stage Bio Technology [Member]          
Segment Reporting [Line Items]          
Other income (expense) [1] (3,993) 972  
Total loss before income taxes (1,300,745) (1,855,153) (2,947,875) (4,396,857)  
Clinical Stage Bio Technology [Member] | Continuing Operations [Member]          
Segment Reporting [Line Items]          
Total assets    
Loss from operations (1,428,594) (3,472,642)  
Consolidated total loss before income taxes (1,432,587)   (3,471,670)  
Clinical Stage Bio Technology [Member] | Discontinued Operations [Member]          
Segment Reporting [Line Items]          
Total assets 700,997   700,997   $ 5,181,535
Loss from operations (1,300,745) (422,566) (2,947,875) (925,187)  
Consolidated total loss before income taxes $ (1,300,745) $ (422,566) $ (2,947,875) $ (925,187)  
[1] Other income (expense) consists of interest income and interest expense.